Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

Conditions:   Small-cell Lung Cancer;   Soft Tissue Sarcoma;   Triple-negative Breast Cancer;   Ovarian Cancer Intervention:   Drug: Tinostamustine (EDO-S101) Sponsor:   Mundipharma-EDO GmbH Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials